|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-1.58/-4.52
|
企業價值
2.54B
|
資產負債 |
每股賬面淨值
9.56
|
現金流量 |
現金流量率
--
|
損益表 |
收益
377.71M
|
每股收益
0.98
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/12/24 12:38 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making adouble-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201. |